Thalassemia Treatment Market Expected to Reach USD 1.5 billion by 2031, with a Projected CAGR of 7.3%: Transparency Market Research, Inc.

Stem cell therapy is gaining traction for the treatment of thalassemia, especially for severe cases. Gene-edited cell therapy is also gaining popularity for the treatment of transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older.Wilmington, Delaware, United States, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global thalassemia treatment market is slated to be valued at US$ 1.5 billion in 2031, with an expected value CAGR of 7.3%. Thalassemia is

Related Keywords

United States ,Boston ,Massachusetts ,Delaware ,India ,Canada ,America ,Asia Pacific ,Vifor Pharma ,Nikhil Sawlani ,Bluebird Bio Inc ,Drug Administration ,Healthcare Regulatory Agency ,Transparency Market Research ,Premium Research ,Novartis ,Bellicum Pharmaceuticals ,Customization Request For The Research ,Takeda Pharmaceutical Company Limited Incyte Corporation ,Merck Co Inc ,Transparency Market Research Inc ,Celgene Corporation ,Market Research ,Boston Children ,Market Drivers ,Thalassemia Treatment ,Middle East ,South Asia ,Research Report ,North America ,Takeda Pharmaceutical Company Limited ,Incyte Corporation ,Premium Research Report ,Trending Reports ,Genomics Market ,Migraine Treatment Market ,Canada Toll Free ,Chelation Therapy ,Thalassemia Patients ,Blood Transfusion ,Gene Therapy ,Global Market ,